DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook

 

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

• June 2024:- Argenx– A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis.
• June 2024:- Axoltis Pharma– A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c.
• June 2024:- Biogen– A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation. The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF).
• DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
• The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Promising Amyotrophic Lateral Sclerosis Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.

 

Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment

 

Amyotrophic Lateral Sclerosis Emerging Drugs Profile

• MN-166: MediciNova

MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.

• RNS60: Revalesio

RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.

• VM202: Helixmith

VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.

• QRL-201: QurAlis Corporation

QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the Amyotrophic Lateral Sclerosis treatment.

 

Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis Research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs

 

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives

 

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report

• Coverage- Global
• Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Amyotrophic Lateral Sclerosis Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MN-166: MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. QRL-201: QurAlis Corporation
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Amyotrophic Lateral Sclerosis Key Companies
21. Amyotrophic Lateral Sclerosis Key Products
22. Amyotrophic Lateral Sclerosis- Unmet Needs
23. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
24. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
25. Amyotrophic Lateral Sclerosis Analyst Views
26. Amyotrophic Lateral Sclerosis Key Companies
27. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/